Replies to post #3056 on Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[carl_52fl]

Dutton's report is a very thorough, conservative estimate. Its price target of 0.42, a 60% discount to its peers, will be upgraded closer to the 21.2 average PE of its peers, once GTEC puts in a couple of solid quarters. This valuation at 21.1 PE is over a buck.
I believe that the old GTEC was still owed these reports by Dutton, since they had a year contract with them starting mid-2007.
I'm sure we all would want to see a bigger price target immediately, but I guess we have to climb one hill at a time.

[Long-vestor]

I think that's rather conservative, considering the CEO's statement regarding income last October at 8 Million, for that month alone. While the company has not posted an income statement since, when the financials are released and if there was no further growth in monthly income, despite the release of Baobaole Chewable Tablets, which ought to have boosted it.. Only 8x3 means one of the highest quarterly reports to date.. $24 million..

If that is reported, short term valuation or target should be .85 unadventurously.

I think the market is stalling, waiting to see the proof in the pudding.. Once that’s done,, we are on our way..